241 related articles for article (PubMed ID: 37180585)
1. EIF4A3 serves as a prognostic and immunosuppressive microenvironment factor and inhibits cell apoptosis in bladder cancer.
Hu B; Chen R; Jiang M; Xiong S; Liu X; Fu B
PeerJ; 2023; 11():e15309. PubMed ID: 37180585
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
3. Identification of m6A suppressor EIF4A3 as a novel cancer prognostic and immunotherapy biomarker through bladder cancer clinical data validation and pan-cancer analysis.
Yan H; Zhang L; Li R
Sci Rep; 2023 Sep; 13(1):16457. PubMed ID: 37777564
[TBL] [Abstract][Full Text] [Related]
4. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
Li JD; Farah AA; Huang ZG; Zhai GQ; Wang RG; Liu JL; Wang QJ; Zhang GL; Lei ZL; Dang YW; Li SH
BMC Cancer; 2022 Jun; 22(1):713. PubMed ID: 35768832
[TBL] [Abstract][Full Text] [Related]
7. hsa_circ_0101119 facilitates the progression of cervical cancer via an interaction with EIF4A3 to inhibit TCEAL6 expression.
Sui X; Wang Y; Liu H
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278492
[TBL] [Abstract][Full Text] [Related]
8. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
9. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
10. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
12. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
13. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X
BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
Front Immunol; 2023; 14():955949. PubMed ID: 37006317
[TBL] [Abstract][Full Text] [Related]
15. KLK6 Functions as an Oncogene and Unfavorable Prognostic Factor in Bladder Urothelial Carcinoma.
Zhao K; Gao M; Lin M
Dis Markers; 2022; 2022():3373851. PubMed ID: 36193495
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of circSMAD2 inhibits the tumorigenesis of gallbladder cancer through binding with eIF4A3.
Qin Y; Zheng Y; Huang C; Li Y; Gu M; Wu Q
BMC Cancer; 2021 Nov; 21(1):1172. PubMed ID: 34727877
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
Qiu Y; Ye W; Wang C; Zang J
Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
[TBL] [Abstract][Full Text] [Related]
18. A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer.
Chen X; Liao C; Zou X; Zhang B; Mo Z
Clin Transl Oncol; 2024 Feb; 26(2):477-495. PubMed ID: 37594617
[TBL] [Abstract][Full Text] [Related]
19. HYAL3 as a potential novel marker of BLCA patient prognosis.
Liu JP; Fang YT; Jiang YF; Lin H
BMC Genom Data; 2022 Aug; 23(1):63. PubMed ID: 35945500
[TBL] [Abstract][Full Text] [Related]
20. ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer.
Jiang YK; Shuai YJ; Ding HM; Zhang H; Huang C; Wang L; Sun JY; Wei WJ; Xiao XY; Jiang GS
Curr Med Sci; 2023 Jun; 43(3):560-571. PubMed ID: 37142816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]